BioSpace News Archive

Puma Biotechnology, Inc. announced that in connection with the appointment of Jeff Ludwig as Puma’s Chief Commercial Officer, the Compensation Committee of Puma’s Board of Directors approved a grant to Mr. Ludwig of an inducement stock option to purchase 320,000 shares of Puma common stock, at an exercise price per share equal to the closing price of Puma’s common stock on the grant date.

FDA gives emergency use authorization of “Y” splitter tubing to allow a single ventilator to assist up to four patients

Grifols announces that it has entered into a formal collaboration with the US Biomedical Advanced Research Development Authority, the FDA and other Federal public health agencies to collect plasma from convalescent COVID-19 patients, process this specific plasma into a hyperimmune globulin and support the necessary preclinical and clinical studies to determine if anti-SARS-CoV-2 hyperimmune globulin therapy can successfully be used to treat COVID-19 disease.

The Prime Minister will address Canadians on the COVID-19 situation, and a media availability will follow.

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a life sciences company focused on the research and development of therapeutics for rare disorders and infectious diseases, is pleased to announce that the Company has retained Pharm-Olam, LLC,

Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”) today announced that it will report its Fourth Quarter and full Fiscal Year 2019 financial results after the close of market on March 30, 2020.

Company’s Leap-In Transposase® platform enables the rapid large-scale production of proteins critical to the development of diagnostics, vaccines and therapeutics

Innovent Biologics, Inc. and Alector, Inc. jointly announced that they have entered into a licensing agreement to develop and commercialize an anti-SIRP-alpha antibody for the treatment of oncology indications in China.

Adjusted EBITDA reaches $4.2 million and Net income increases to $2.6 million in the fourth quarter

Clinical data supports continued development of telacebec toward the first universal regimen to overcome tuberculosis regardless of drug resistance status